Delaware | 001-36257 | 27-4842691 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
3721 Valley Centre Drive Suite 200, San Diego, CA 92130 |
(Address of Principal Executive Offices, including Zip Code) |
(760) 260-8600 |
(Registrant’s Telephone Number, including Area Code) |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.0001 per share | RTRX | The Nasdaq Global Market |
• | Stock option awards (the “Options”) to Noah Rosenberg, Laura Clague, William Rote, Ph.D. and Elizabeth Reed to purchase 40,000 shares each of the Company’s common stock, respectively, at an exercise price equal to $17.96 per share, the closing price of the Company’s common stock on the date of grant. One-quarter of the Options vest on the one year anniversary of the date of grant and the remaining three quarters vest in monthly installments over the subsequent three years. |
• | Restricted stock unit awards (the “RSUs”) to Noah Rosenberg, Laura Clague, William Rote, Ph.D. and Elizabeth Reed covering 6,000 shares each of the Company’s common stock, respectively. The RSUs vest annually over four years. |
• | Performance-based restricted stock unit awards (the “PRSUs”) to Eric Dube, Noah Rosenberg, Laura Clague, William Rote, Ph.D. and Elizabeth Reed covering 6,000 shares each of the Company’s common stock, respectively. The PRSUs vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. |
RETROPHIN, INC. | ||||
Dated: May 13, 2018 | By: | /s/ Elizabeth E. Reed | ||
Name: | Elizabeth E. Reed | |||
Title: | Senior Vice President, General Counsel and Secretary |